Condition: Cholera Vaccination · Sponsor: International Vaccine Institute
This phase II study is intended to determine the immunogenicity and safety of single dose and two doses of OSP:rTTHc cholera conjugate vaccine (CCV) with or without alum adjuvant. The study will guide the future dosing schedule and formulation of CCV (with or without Aluminum phosphate adjuvant) expected to be needed in adults and children in cholera-endemic region.
This description comes directly from the study's public registry record.
Naveena D'Cor, MD · +82 2 8811 000 · naveena.dcor@ivi.int
Tarun Saluja, MD · +82 2 8811 000 · Tarun.Saluja@ivi.int
Always discuss trial participation with your own doctor first.
| KAVI-Institute of Clinical Research, University | Nairobi, Kenyatta National Hospital Complex, Kenya | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07509047